← Back to headlines
Biotech Firms Outline Financial Runways and Product Development Timelines
Dyadic and Altimmune, two biotech companies, have provided updates on their financial stability, outlining cash runways extending into 2027 and 2029 respectively. They also detailed timelines for key product development milestones, including alpha-lactalbumin sampling and the start of a Phase III MASH trial.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
